July 18, 2024

Acino integrates with Pharmax Pharmaceuticals boosting the portfolio in ME

Facebook
Twitter
LinkedIn
Aesch Farbe

Acino, a Swiss pharmaceutical company headquartered in Zurich, recently announced the integration of Pharmax Pharmaceuticals, a UAE-based manufacturer and distributor of high-quality medications. Both companies are owned by ADQ, an Abu Dhabi-based investment and holding company.

With the integration of Pharmax, Acino will add over 100 employees and a GCC and EU GMP-certified manufacturing site, complementing its operational capabilities and expanding its growing international footprint. Equipped to manufacture various dosage forms, including tablets, capsules, inhalers, injectables, and topicals, the newly added facility adheres to the high-quality standards set by the regulatory authorities in the UAE and Europe.

Sunil Bhilotra, Managing Director and interim CEO of Acino

Sunil Bhilotra, Managing Director and interim CEO of Acino stated “The integration of Pharmax Pharmaceuticals into Acino will accelerate our efforts towards becoming a leading provider of high-quality pharmaceuticals in the Middle East and beyond. We will advance our ability to distribute high-quality medicines to markets across the globe and achieve even greater levels of growth and innovation across the pharma value chain.”

Andrew Bird, Head of Region, Middle East, Turkey, and Africa, at Acino

“With this change, we are positioning ourselves at the forefront of the rapidly expanding pharmaceutical market in the UAE,” said Andrew Bird, Head of Region, Middle East, Turkey, and Africa, at Acino. “Our combined expertise alongside the support of ADQ will enable us to contribute to the UAE’s efforts of becoming a leading pharmaceutical hub and tap into the great potential of the region.”

Madhukar Tanna, CEO of Pharmax

“Our industry is continuously evolving, and this step will help both organizations deliver continued value to our patients and customers,” said Madhukar Tanna, CEO of Pharmax. “By integrating our workforce, products, and operations, we are building a stronger platform for the future.”

Aesch (Farbe) Pharmaceutical Market

According to the whitepaper by ADQ, the UAE’s pharmaceutical market is expected to grow by 27 percent between 2021 and 2025, reaching a value of $4.7 billion. The number of manufacturing units in the country reached 23 in 2021, up from four in 2010, with 14 producing medicines, four manufacturing medical devices, and two focused on disinfectant solutions. There are now more than 2,500 medicines produced locally.

The combined company will be able to leverage synergies across main therapeutic areas and share best practices, advancing product development capabilities and further strengthening Acino’s robust commercial performance.

Press Release received on Mail

Also on Acino:

Acino’s digital series raises awareness on Cardiovascular diseases

Acino and Pharmax collaborate to align with UAE’s strategy to become a regional pharmaceutical manufacturing hub

Share.

RELATED POSTS

Red Sea Global unveils new WAMA sailing club
Red Sea Global launches new WAMA sailing club
CENTOGENE and Lifera ink agreement
CENTOGENE and Lifera ink agreement
Makani chooses Yardi for portfolio management
Makani chooses Yardi for portfolio management
  • logo banner warba
  • Mutual Trust Bank Plc
  • Ahli United Bank

LATEST POSTS

The business landscape is going through continuous change, which means that there are constantly new challenges arising in HR. This blog entails on few of the major challenges arising in 2024
Representational Image
ACCA announces the addition of new Emirati members to its Members’ Advisory Committee with a government-led goal of achieving a 10% increase in Emiratisation of the skilled workforce by 2026
CyberKnight announces VAD partnership with Forescout for META. CyberKnight to offer complete asset intelligence and control across IT, OT, and IoT to Forescout.